Meridian Bioscience, Inc. (VIVO) Misses Q2 EPS by 3c; Cuts FY14 Outlook
Get Alerts VIVO Hot Sheet
Price: $33.97 --0%
Revenue Growth %: -100.0%
Financial Fact:
OPERATING INCOME: 8.9M
Today's EPS Names:
WF, CWBC, GLTO, More
Revenue Growth %: -100.0%
Financial Fact:
OPERATING INCOME: 8.9M
Today's EPS Names:
WF, CWBC, GLTO, More
Join SI Premium – FREE
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q2 EPS of $0.24, $0.03 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $50.13 million versus the consensus estimate of $52.18 million.
Meridian Bioscience, Inc. sees FY2014 EPS of $0.85-$0.90, versus prior guidance of $0.98-$1.03 and the consensus of $0.97. Meridian Bioscience, Inc. sees FY2014 revenue of $190-195 million, versus prior guidance of $203-208 million and the consensus of $201.05 million.
For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- European stocks rise, helped by positive global sentiment; NatWest gains
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!